● Live Wisconsin AG suit vs Kalshi & Polymarket pending · NY/IL insider-trading orders in effect · Updated May 2026
← News & Updates
Regulation

Fourth Circuit Rules Against Kalshi in Maryland — Circuit Split Widens to 3-1 With a Notable Dissent

A divided Fourth Circuit panel ruled 2-1 on November 17 that Maryland gaming regulators can pursue enforcement against Kalshi over unlicensed sports betting, rejecting the platform's CFTC-preemption argument. Judge DeAndrea Benjamin dissented, arguing that Kalshi's sports event contracts are 'swaps' under exclusive CFTC oversight — the first appellate dissent on the pro-Kalshi side. The ruling makes the Fourth Circuit the third appeals court to rule against Kalshi, deepening the split to three circuits against (Fourth, Sixth, Ninth) and one for (Third), with the Supreme Court cert petition pending.

A divided panel of the Fourth Circuit Court of Appeals ruled 2-1 on November 17, 2026 that Maryland gaming regulators may pursue enforcement against Kalshi for offering unlicensed sports betting, rejecting Kalshi's argument that the Commodity Exchange Act gives the CFTC exclusive jurisdiction over its sports event contracts and preempts state gambling law. The ruling adds the Fourth Circuit to the growing list of appeals courts siding with states against Kalshi, in a Mid-Atlantic circuit covering Maryland, Virginia, the Carolinas, and West Virginia. Kalshi had sought to prevent Maryland from policing its platform; the decision lets the state's enforcement proceed.

For UK readers, the dissent is the ruling's most legally significant feature. Judge DeAndrea Benjamin dissented from the 2-1 majority, arguing that Kalshi's sports event contracts are 'swaps' under the Commodity Exchange Act and therefore fall under exclusive CFTC oversight — the core of Kalshi's preemption case. This is the first appellate-level dissent on the pro-Kalshi side. The earlier rulings against Kalshi, from the Ninth and Sixth Circuits, were unanimous; the Fourth Circuit's 2-1 split with a reasoned dissent shows the swap-definition question genuinely divides judges, not just circuits. A dissent matters for the Supreme Court's cert calculus: it shows the question is close enough to produce disagreement even within a single panel, strengthening the argument that it warrants definitive resolution, and it gives Kalshi a judicial voice endorsing its interpretation at the appellate level outside the Third Circuit.

The ruling deepens the circuit split to its widest point yet: three circuits have now ruled against Kalshi (Fourth, Sixth, Ninth) and one for it (Third). The directional trend is unfavourable — three of the four circuits to decide the merits have held that states can regulate the contracts as gambling, and only the Third accepted CFTC preemption. More circuits are in the pipeline: the Eighth is weighing Kalshi's Iowa appeal and the Arkansas case, the Fifth now has the Louisiana litigation, the Tenth has ruled against Kalshi in the Utah-related matter, and the Second has the New York appeals. The more circuits rule against Kalshi, the stronger the case for Supreme Court review — but also the more appellate authority accumulates against the platforms' position, which could shape how the Court approaches the merits if it grants cert.

The timing reinforces the pressure on the Supreme Court. New Jersey's cert petition, from the Third Circuit's pro-Kalshi ruling, is pending, with Kalshi's response due December 7. A three-to-one split with a dissent in the most recent ruling is close to an ideal cert posture: a genuine, deepening, judicially-contested conflict on an important federal question with billions in commerce at stake. The Court is more likely to grant review when the lower courts are both divided and actively producing new conflicting decisions, and the Fourth Circuit ruling is the latest evidence the disagreement is not resolving on its own. For the platforms, the accumulation of adverse rulings is double-edged: each loss expands the set of states that can enforce in the near term, but it makes Supreme Court review — the platforms' best path to a definitive national victory — more probable. Kalshi's strategy has effectively become a bet that the Court will take the case and reverse the majority of circuits, restoring the Third Circuit's pro-preemption position as the national rule. The Fourth Circuit ruling makes that bet both more necessary and higher-stakes.

Operators mentioned in this article


Recent updates


CFTC Orders Kalshi to Halt 'Trump Mention' Markets — the Agency Restrains Its Own Protégé

The CFTC notified Kalshi that its 'mention' markets — contracts on what President Trump will say — are under a formal stay, forcing an indefinite pause pending a review of whether the contracts are 'readily susceptible to manipulation.' Kalshi has until December 11 to defend the products, and its CEO reportedly disagrees with the suspension. The action is notable because the CFTC has spent 2026 defending Kalshi against state enforcement; here the same agency is restricting one of Kalshi's own product lines.

CFTC and DOJ Sue Louisiana and Arkansas as Federal-State Fight Turns Openly Hostile

Louisiana Attorney General Liz Murrill won a temporary restraining order on November 12 against 31 prediction market entities, including Kalshi, Polymarket, Robinhood, and Coinbase, with a preliminary injunction hearing set for November 30. The CFTC — now joined by the Department of Justice — sued both Louisiana and Arkansas to block the state enforcement, marking Louisiana as the twelfth state the agency has taken to court. The dispute has turned personal: Murrill called CFTC Chairman Michael Selig an 'obsequious standard bearer' for the platforms, while Selig characterised her lawsuit as 'naked lawfare.' The DOJ's involvement escalates the federal response beyond the CFTC acting alone.

Kalshi and Polymarket Expand Into Health Contracts — Measles, Drug Trials, FDA Approvals Draw Scrutiny

Kalshi and Polymarket have added event contracts tied to US public health outcomes, including measles case-count thresholds settled using CDC data, clinical drug-trial results, and FDA regulatory approvals. Two Democratic senators wrote to the Department of Health and Human Services on November 11 raising concerns about the drug-trial and FDA markets, particularly the risk that people with confidential access to trial data or agency decisions could profit from disclosing it. Kalshi says it has implemented guardrails, such as limiting markets to late-stage trials. The expansion extends the debate over whether some prediction market categories commodify sensitive public outcomes in harmful ways.